Impact of Renin-Angiotensin System Inhibitors on Disease Characteristics in Patients with Localized Prostate Cancer Treated with Radical Prostatectomy: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study.

BACKGROUND AND OBJECTIVE

Collagen biosynthesis is intricately involved in the development and progression of solid tumors. Renin-angiotensin system inhibitors (RASi) impede TGF-β-mediated collagen synthesis in tumors by hindering activation of the angiotensin receptor. Our aim was to investigate a potential association between RASi use and the aggressiveness of prostate cancer (PCa).

METHODS

We conducted a retrospective multicenter analysis for a cohort of 1250 patients with PCa who underwent radical prostatectomy (RP) between 1990 and 2023 in four European high-volume centers. The study cohort comprised 625 RASi-treated patients and 625 age-matched RASi-naïve patients. Data for various parameters were collected, including age at RP, body mass index (BMI), prostate volume, prostate-specific antigen (PSA), percentage of free PSA, Gleason score (GS) at biopsy and RP, TNM stage, and the rate of biochemical recurrence (BCR). Clinical parameters for patients with and without RASi treatment were documented. Differences between the groups were compared using a Mann-Whitney U test and χ tests. Survival analyses were performed using the Kaplan-Meier method.

KEY FINDINGS AND LIMITATIONS

As expected, the RASi group had higher BMI levels than the RASi-naïve group ( < 0.001). However, RASi use was not associated with key markers of PCa aggressiveness such as GS upgrading from biopsy to RP ( = 0.089), surgical margin status ( = 0.109), and lymph node involvement ( = 0.33). Moreover, there were no significant differences between the groups in BCR incidence ( = 0.258) or the time to BCR ( = 0.683).

CONCLUSIONS AND CLINICAL IMPLICATIONS

Our findings indicate that RASi therapy does not have a significant effect on the biological aggressiveness of PCa.

PATIENT SUMMARY

We analyzed data for 1250 patients with prostate cancer and found that the use of a commonly prescribed high blood pressure medication was not associated with a less aggressive form of localized prostate cancer.